GH
T2Guardant Health, Inc.
AI '25: Data OwnersAI '25: Healthcare ApplicationsData Owners '25: Healthcare, Claims & Clinical DataGenomics '25: Molecular Diagnostics & Clinical GenomicsInfra Built in ZIRP '25: HC PlatformsMedTech Long '25: Cancer Diagnostics, Platforms & CareMedTech Long '25: Centralized Lab DiagnosticsMedTech Long '26: Diagnostics & Early Detection
Loading chart…
OverviewGuardant Health, Inc. develops blood tests and data solutions for cancer care. Its Guardant360 (now FDA-approved Liquid CDx) and Reveal oncology tests guide tre
Guardant Health, Inc. develops blood tests and data solutions for cancer care. Its Guardant360 (now FDA-approved Liquid CDx) and Reveal oncology tests guide treatment and monitor advanced and early-stage cancers. The Shield test, with ACS guideline inclusion and UnitedHealth coverage, offers early colorectal and multi-cancer detection. In Q2 2026, oncology was ~65% of revenue, biopharma ~18%, and screening ~16%, serving physicians, patients, and pharmaceutical firms.
Search Keywords Brand Product
- Guardant360 Liquid
- Guardant360 CDx
- Guardant Reveal
- Shield blood test
- Reveal Ultra
- InfinityAI
- Smart Platform
- liquid biopsy
- cancer screening
- precision oncology
- minimal residual disease
- therapy selection
- multi-cancer detection
- genomic profiling
Search Keywords Event Phrases
- Guardant Health Q2 earnings 2026
- Guardant360 Liquid CDx FDA approval
- Shield UnitedHealth coverage
Search Keywords Policy Regulatory
- FDA approval diagnostics
- ADLT designation
- ACS guidelines
- UnitedHealth Group coverage
- MolDx reimbursement
- What They Do (Plain English & Analogies)
- Guardant Health is a company that helps doctors fight cancer using advanced blood tests, often called "liquid biopsies." Instead of needing a piece of tissue from a tumor, they can find tiny fragments of cancer DNA in a patient's blood. This allows doctors to choose the best treatments, monitor if those treatments are working, and even screen for cancer early, like for colorectal cancer. Think of it like a highly sensitive "bloodhound" for cancer, sniffing out even the smallest traces of the disease to guide patient care. They also partner with drug companies to help develop new cancer medicines and provide valuable data insights, all powered by their Smart Platform and InfinityAI.
- Very Brief History
- Guardant Health, Inc. was founded in 2011 by Helmy Eltoukhy and AmirAli Talasaz, becoming a leader in precision oncology. The company went public in 2018. Key milestones include FDA approval for Guardant360 CDx in 2020, the launch of Guardant Reveal in 2021, and FDA approval of its Shield blood test for colorectal cancer screening in 2024. In Q2 2026, Guardant Health received FDA approval for Guardant360 Liquid CDx and a higher-throughput, lower-COGS Shield workflow.
- "Street Stereotype"
- Guardant Health is generally perceived as a leading innovator in precision oncology, particularly in the liquid biopsy space. Investors and analysts view them as a company that has successfully built out a strong technological platform and data network, leveraging infrastructure developed during the ZIRP era. They are seen as a key player in the shift towards personalized medicine and early cancer detection, with significant growth potential in centralized lab diagnostics, especially with their Shield colorectal cancer screening test. They are also recognized for their integration of AI into their data-rich workflows.
- Subsidiaries On Linked In*
- Guardant Health AMEA — Located in Singapore, founded in 2012.
- Customer Sectors & Example Clients
- Guardant Health's customers are primarily in the healthcare sector, including oncologists, primary care physicians, and health systems. They also serve biopharmaceutical companies and medical institutions. Specific example clients mentioned include UnitedHealth Group (for coverage of Shield), Quest Diagnostics (for national sales and connectivity system integration for Shield), Boehringer Ingelheim, Arvinas and Pfizer, and Nuvalent (for companion diagnostic development).
- New Customers / Segments They'Re Targeting
- Guardant Health is actively targeting the under-65 commercial population for its Shield colorectal cancer screening test, following recent guideline inclusions and coverage decisions. They are also focused on expanding the use of Reveal for therapy monitoring in late-stage cancer patients, which represents a multi-million test annual opportunity. Additionally, the company is expanding Shield internationally through self-pay channels.
- Supply Chain And Sourcing Geographies
- Guardant Health manages its supply chain operations, including procurement, planning, inventory, and supplier relationships. The company's Senior Vice President of Operations oversees clinical sample production, manufacturing, facilities, and supply chain for its in vitro diagnostic (IVD) products. The company recently completed the Guardant360 Liquid transition to NovaSeq X, implying sourcing of sequencing technology. While specific sourcing geographies are not explicitly detailed, the company emphasizes responsible supply chain operations and works with over 3,000 active suppliers.
- Sales Geographies And Expansion Plans
- Guardant Health currently sells its products within the United States and internationally, operating in the Americas, Europe, and Asia, Middle East, Africa (AMEA) regions. Their companion diagnostic franchise spans approvals across the U.S., Japan, and Europe. The company is expanding Shield internationally through its self-pay channel, with existing partnerships like Manulife for Shield Multi-Cancer Detection in Hong Kong, the Philippines, and Singapore.
- How Key Themes May Help/Hurt
- Guardant Health is well-positioned to benefit from the 'MedTech Long '26: Diagnostics & Early Detection' theme due to accelerating technological advancements in genomics and AI (e.g., its Smart Platform and InfinityAI), increasing demand for advanced diagnostic solutions driven by cancer prevalence, and favorable regulatory developments such as FDA approvals for Guardant360 Liquid CDx and Shield's inclusion in ACS guidelines and UnitedHealth Group coverage. However, the company could be hurt by persistent reimbursement pressures, particularly the anticipated decline in Shield's average selling price (ASP) due to a changing mix towards commercially insured patients under 65, where rates may be lower. Additionally, significant regulatory hurdles for new indications and intensifying competition in the liquid biopsy and cancer screening markets could impact profitability and market uptake.
3 Main Long-Term Bull Details
- Comprehensive Smart Platform and AI-Driven Innovation: Guardant's 'Smart Platform' and 'InfinityAI' leverage a vast and growing proprietary data asset (over 1.3 million patient tests and 700,000 epigenetic profiles) to drive continuous innovation, develop new clinical applications (Smart apps), and accelerate drug discovery, creating a strong and compounding competitive moat.
- Rapidly Scaling Screening Business with Expanding Coverage: Shield's strong volume growth, inclusion in American Cancer Society (ACS) colorectal cancer screening guidelines, and a major coverage decision from UnitedHealth Group (the largest commercial insurer) significantly expand its addressable market and accelerate adoption, further supported by a new higher-throughput, lower-COGS workflow.
- Accelerating Oncology Portfolio Growth and Robust Pipeline: The company is experiencing strong, broad-based growth across its oncology portfolio, with Guardant360 Liquid volumes accelerating (>30% Y/Y), Guardant360 Tissue as the second fastest-growing product, and Reveal leading with over 100% Y/Y volume growth driven by MRD and therapy monitoring. The recent FDA approval of Guardant360 Liquid CDx and the upcoming launch of Reveal Ultra further strengthen its oncology offerings.
3 Main Long-Term Bear Details
- Significant Cash Burn in Screening Business: Despite strong revenue growth, the Shield screening business continues to incur substantial cash burn, requiring accelerated investments in lab capacity and commercial expansion, which delays the overall company-wide free cash flow positivity target.
- Potential for Shield ASP Decline and Reimbursement Challenges: While Shield's ADLT rate is stable, its average selling price (ASP) is expected to decline for the remainder of 2026 due to a changing mix with increasing demand from the under-65 commercial population, where reimbursement rates may be lower or less consistent than Medicare. Delays in MolDx coverage decisions for Reveal also pose a risk.
- Intensifying Competition and Regulatory Hurdles: The liquid biopsy and cancer screening markets are highly competitive, with established players and new entrants (e.g., Freenome, Abbott) vying for market share, potentially leading to pricing pressures and increased commercialization costs. Ongoing regulatory and evidence generation challenges for new indications and products, such as the USPSTF review for Shield, could impede market access and growth.
- Competitors And Differentiation
- Guardant Health operates in a competitive market for liquid biopsy and cancer screening. Competitors include companies like Exact Sciences (Cologuard), Natera (Signatera), Freenome (SimpleScreen CRC), and Abbott (Cologuard, SimpleScreen CRC). Guardant differentiates itself through its comprehensive 'Smart Platform' and 'InfinityAI' offerings, which integrate genomic and epigenomic content for deeper insights. Guardant360 Liquid CDx is highlighted as the only FDA-approved liquid biopsy test integrating both genomic and epigenomic content. Reveal is positioned as the most validated and highest performing tissue-free MRD solution with a rapid turnaround time. The company also emphasizes its vast proprietary data asset (over 1.3 million patient tests) as a difficult-to-replicate advantage.
- Recent Performance & What The Market'S Focused On
- Guardant Health delivered strong Q2 2026 results, with revenue reaching $335 million, up 44% year-over-year. This growth was broad-based across Oncology (up 38%), Biopharma & Data (up 9%), and Screening (up from $15 million to $53 million). Oncology test volumes rose 63% to approximately 104,000 tests, and Shield volumes increased to 66,000 tests. The company raised its full-year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, representing 36% to 38% growth. The market is currently focused on the impact of the recent FDA approval for Guardant360 Liquid CDx and its anticipated ADLT designation in the first half of 2027, the inclusion of Shield in American Cancer Society colorectal cancer screening guidelines, and the major coverage decision from UnitedHealth Group for Shield. Investors are also tracking the launch of Reveal Ultra, broader Reveal reimbursement, and the company's commitment to achieving company-wide cash flow breakeven by the end of 2027.
- Revenue Segments And Estimated Mix
- Oncology — Mix: ~65.4%; Source: Q2 2026 transcript; Trend: Grew 38% year-over-year to $219 million in Q2 2026.
- Biopharma & Data — Mix: ~18.2%; Source: Q2 2026 transcript; Trend: Grew 9% year-over-year to $61 million in Q2 2026.
- Screening — Mix: ~15.8%; Source: Q2 2026 transcript; Trend: Grew significantly year-over-year to $53 million in Q2 2026 from $15 million in Q2 2025.
- Product Brands
- Guardant360 Liquid
- Guardant360 Tissue
- Guardant360 CDx
- GuardantOMNI
- GuardantINFORM
- Guardant Reveal
- Reveal Ultra
- Shield
- Shield Multi-Cancer Detection (MCD) Report
- GuardantConnect
- Guardant-19
- InfinityAI
- Smart Platform
Bull / Bear DetailsGuardant Health's bullish investment case is significantly strengthened by landmark Q2 2026 achievements, including FDA approval for Guardant360 Liquid CDx and
Thesis
Guardant Health's bullish investment case is significantly strengthened by landmark Q2 2026 achievements, including FDA approval for Guardant360 Liquid CDx and Shield's inclusion in ACS guidelines and UnitedHealth coverage. The company's oncology business is accelerating, and the rapidly scaling Shield screening business, supported by cost efficiencies, drives robust revenue growth. A clear path to profitability for its core business and company-wide cash flow breakeven by late 2027 underpins sustained market leadership in precision oncology and early cancer detection as of 2026-08-07.
Bull case
Guardant's oncology business is demonstrating exceptional and accelerating growth, with Q2 2026 revenue up 38% year-over-year and volume up 63%. Guardant360 Liquid volumes grew over 30%, while Reveal remained the fastest-growing product with over 100% year-over-year volume growth, driven by strong adoption in MRD and therapy response monitoring. The FDA approval of Guardant360 Liquid CDx further strengthens its leadership.
The Shield colorectal cancer screening test is a significant multiyear growth driver, achieving landmark milestones in Q2 2026. Inclusion in American Cancer Society guidelines and UnitedHealth Group's coverage decision for 70 million lives (60% of the market) significantly expands access. Raised 2026 screening revenue guidance to $218M-$230M reflects strong demand and commercial execution.
Guardant Health is demonstrating a clear path to profitability, with the core business (excluding screening) now adjusted EBITDA positive and generating positive cash flow. The company remains committed to achieving company-wide cash flow breakeven by the end of 2027, supported by operational efficiencies like the NovaSeq X transition and the new lower-COGS Shield workflow.
Bear case
The Shield screening business continues to incur significant cash burn, with full-year 2026 free cash flow burn guidance increased to $195M-$205M due to accelerated investments in lab capacity. This heavy investment in commercial expansion and infrastructure for Shield delays overall company-wide free cash flow positivity and introduces execution risk in scaling operations.
While UnitedHealth Group coverage is a major win for Shield, the realization of average selling price (ASP) upside from commercial payers will take time due to negotiation and collection history. Management does not anticipate major additional commercial payer wins in the short term, and none are included in current guidance, creating uncertainty around immediate ASP improvements.
The competitive landscape for new products like Reveal Ultra is acknowledged as "highly competitive," potentially impacting market share and adoption. Additionally, MolDx submissions for Reveal in new indications are taking "a little bit longer than we would have liked," indicating potential delays in securing broader reimbursement and ASP upside for these growth drivers.
Bull / Bear Case
- Bear Case
- Despite strong operational progress, Guardant Health faces significant financial headwinds. The Shield screening business continues to incur substantial cash burn, with full-year 2026 free cash flow burn guidance increased to $195M-$205M due to accelerated investments, delaying overall company-wide free cash flow positivity. While UnitedHealth Group coverage is a major win, the realization of average selling price (ASP) upside from commercial payers will take time due to negotiation and collection history, with no major additional commercial payer wins anticipated in the short term. The competitive landscape for new products like Reveal Ultra is acknowledged as 'highly competitive,' and MolDx submissions for Reveal in new indications are taking 'a little bit longer than we would have liked,' indicating potential delays in securing broader reimbursement.
- Bull Case
- Guardant Health's Q2 2026 performance was exceptional, with 44% year-over-year revenue growth driven by accelerating oncology volumes (38% revenue, 63% test volume, >100% for Reveal). Key regulatory milestones include FDA approval for Guardant360 Liquid CDx and a new lower-COGS Shield workflow. The Shield colorectal cancer screening test achieved landmark commercial wins with ACS guideline inclusion and UnitedHealth Group coverage for approximately 70 million lives, significantly expanding market access. The company is demonstrating a clear path to profitability, with the core business (excluding screening) now adjusted EBITDA positive and a commitment to company-wide cash flow breakeven by the end of 2027, supported by operational efficiencies and a robust product pipeline including Reveal Ultra.
- More Compelling & Why
- Bear. Despite strong operational performance and positive catalysts, the stock appears significantly overvalued. The Price-to-Sales (P/S) ratio of 18.5x is extremely high compared to the US Healthcare industry average of 1.4x and peer average of 1.4x. This, coupled with ongoing unprofitability and substantial free cash flow burn, suggests that much of the future growth is already priced in. The strongest argument for the bear case is the stretched valuation relative to fundamentals. My view would flip to bullish if the company demonstrates a clear and accelerated path to profitability, evidenced by a significant and sustained reduction in free cash flow burn and a positive operating margin, bringing its P/S multiple closer to industry averages.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Shield Test Volume Growth and Commercial Payer Adoption Post-UnitedHealth Group Coverage | Strong Shield volume growth, particularly from commercial payers like UnitedHealth Group, is crucial for scaling the screening business, expanding market access, and accelerating its path to profitability. | Sequential Shield test volumes reported in Q3 and Q4 2026 earnings. Management commentary on the initial impact of UnitedHealth Group coverage (effective August 1, 2026) and the increasing commercial patient mix. | Bullish if Q3 2026 sequential Shield test volume growth exceeds the implied ~12,000 Q-over-Q average from the raised full-year guidance (270,000-285,000 tests), indicating strong uptake from new commercial coverage. | Guardant Health Q3 2026 earnings report (expected late October/early November 2026), SEC filings. | Google Trends: 'Guardant Shield' search volume; news articles on commercial payer coverage for colorectal cancer screening. | Earnest Analytics: Shield test volume data; Definitive Healthcare: Commercial payer coverage updates for Guardant Shield. |
| Launch of Reveal Ultra | The launch of Reveal Ultra, expected to be the most sensitive tumor-informed MRD test, could significantly enhance Guardant's competitive position and drive further volume growth in the high-potential minimal residual disease (MRD) market. | Official announcement from Guardant Health regarding the launch of Reveal Ultra, including specific indications, performance data, and commercial strategy. | Bullish if Reveal Ultra is launched later in 2026 as planned, with compelling performance data (e.g., LoD levels well below 1 part per million) and a clear commercialization roadmap. | Guardant Health press releases, investor presentations, Q3/Q4 2026 earnings calls. | Industry conference presentations (e.g., ASCO, AACR) for new data; relevant oncology forums/subreddits for physician feedback. | Thinknum: Job postings for 'Reveal Ultra sales specialist'; KOL (Key Opinion Leader) surveys on new MRD tests. |
| Guardant360 Liquid CDx ADLT Designation and Widespread Availability | ADLT designation for Guardant360 Liquid CDx is critical for securing a higher Medicare reimbursement rate ($8,455 vs. current $5,000), significantly improving ASP and profitability for the core oncology business. | Official announcement from Guardant Health or CMS regarding ADLT designation for Guardant360 Liquid CDx. Management commentary on the timeline for widespread commercial availability post-designation. | Bullish if ADLT designation is received in the first half of 2027 as planned, leading to an ASP uplift towards the $8,455 Medicare price over the subsequent 12-24 months. | Guardant Health press releases, SEC filings, CMS announcements. Q4 2026 and Q1 2027 earnings calls. | Industry news sites (e.g., Fierce Biotech, GenomeWeb) covering ADLT designations for liquid biopsies. | Definitive Healthcare: Guardant360 ADLT status and reimbursement updates. |
| MolDx Coverage Decisions for Reveal (Breast Cancer, Immuno-Oncology, Chemotherapy Monitoring) | Positive MolDx coverage expands the addressable market and improves average selling price (ASP) for Reveal, a key growth driver in early-stage cancer and therapy monitoring, validating its clinical utility. | Official announcements from Guardant Health or MolDx regarding coverage decisions for breast cancer surveillance, immuno-oncology monitoring, or chemotherapy monitoring. Management commentary on anticipated ASP upside. | Bullish if MolDx grants positive coverage for at least one of these submitted indications (breast cancer or immuno-oncology monitoring) by the end of 2026, as management is hopeful for. | Guardant Health press releases, SEC filings (10-Q, 8-K), MolDx website. Q3 and Q4 2026 earnings calls for management commentary. | Industry news sites (e.g., Fierce Biotech, GenomeWeb) covering MolDx decisions and diagnostic reimbursement updates. | Definitive Healthcare: MolDx coverage updates for liquid biopsy/MRD tests. |
| Realized Reduction in Shield Cost Per Test from New Workflow | The FDA-approved higher-throughput, lower-COGS Shield workflow is expected to reduce the cost per test, directly improving gross margins and accelerating the screening business's path to company-wide profitability. | Management commentary in Q3 and Q4 2026 earnings reports on the implementation progress and specific reduction in Shield cost per test. Monitor non-GAAP gross margin for the Screening segment. | Bullish if Guardant Health confirms a reduction in Shield cost per test by roughly 15% from the current ~$410 by the end of 2026, as projected, and if this translates to improved gross margins. | Guardant Health Q3 and Q4 2026 earnings reports, SEC filings. | N/A (This is an internal operational metric, not typically tracked by free external data sources). | N/A (This is an internal operational metric, not typically tracked by paid external data sources). |
Key Reported Metrics, Reratings Triggers & ResultsShield test volume is a key leading indicator for Screening Revenue, demonstrating the adoption rate and the effectiveness of commercialization efforts, includi
Upcoming print · 2026-10-28
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Shield Test Volume | 312.5% | Shield test volume is a key leading indicator for Screening Revenue, demonstrating the adoption rate and the effectiveness of commercialization efforts, including the Quest collaboration and new payer coverage. |
| Oncology Revenue | $219 million (38% y/y growth) | As the largest revenue segment, sustained and accelerating growth in Oncology, driven by Guardant360 Liquid and Reveal, is fundamental to Guardant Health's overall financial performance and its path to company-wide cash flow breakeven. |
| Screening Revenue | $53 million (253.3% y/y growth) | This metric directly reflects the impact of recent major wins like ACS guideline inclusion and UnitedHealth Group coverage, which are expected to significantly expand market access and drive volume for the Shield test. Continued strong growth validates the early detection strategy. |
Last reported · 2026-07-30
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Reveal Volume Growth | >100% | Reveal is Guardant Health's fastest-growing oncology product, reflecting strong adoption in MRD and therapy response monitoring. Continued high volume growth, coupled with potential ASP upside from MolDx reimbursement decisions, is critical for expanding its market leadership and contributing to oncology segment growth. | For Guardant Health's stock to rerate higher, Reveal Volume Growth needs to demonstrate sustained triple-digit year-over-year growth, ideally accelerating beyond the Q1 2026 rate of >100%. This acceleration should be accompanied by positive MolDx coverage decisions for new indications, such as breast cancer surveillance or immuno-oncology/chemotherapy monitoring. | Sustained and accelerated Reveal volume growth, particularly with expanded reimbursement, validates Guardant Health's leadership in minimal residual disease (MRD) testing and its 'Smart Platform' strategy. This drives overall oncology revenue, improves the company's path to profitability, and strengthens its competitive position in the high-growth precision oncology market, justifying a higher valuation. | More than 100% y/y growth (accelerating) | Partially | Reveal volume growth accelerated again to more than 100% year-over-year, demonstrating sustained triple-digit growth. However, while MolDx submissions for new indications (breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring) are progressing, no definitive positive coverage decisions were announced in this quarter. Management expressed hope for at least one or both by year-end. | |
| Oncology Revenue | 36% | As the largest revenue segment, sustained strong growth in oncology revenue, driven by Guardant360 and Reveal, is fundamental to Guardant Health's overall financial performance and its stated path to company-wide cash flow breakeven by the end of 2027. | For Guardant Health's stock to rerate higher, Q2 2026 Oncology Revenue growth needs to exceed 30% year-over-year, ideally closer to or above the Q1 2026 rate of 36%. Additionally, a further upward revision to the full-year 2026 oncology revenue growth guidance (currently 28-29%) would signal continued outperformance. | Sustained and accelerating oncology revenue growth, especially above raised guidance, validates Guardant Health's precision oncology leadership and Smart Platform adoption. This signals stronger competitive positioning, potential for earlier profitability, and justifies a higher valuation multiple for its core business, supporting the path to company-wide cash flow breakeven by late 2027. | $219 million (38% y/y growth) | Yes | Oncology revenue grew 38% year-over-year to $219 million, exceeding both the 30% threshold and the prior quarter's 36% growth. The company also raised its full-year 2026 oncology revenue growth guidance to approximately 30%, up from the previous 28-29%, signaling continued outperformance. | |
| Screening Revenue | 600% | Shield's explosive growth is a key driver for Guardant Health's future, with significant investments in commercial expansion and strategic partnerships. Continued strong performance and momentum are crucial for achieving overall revenue targets and demonstrating the success of its early detection strategy. | For Guardant Health's stock to rerate higher, Q2 2026 Screening Revenue should substantially exceed Q1's $41.6 million, ideally reaching at least $55 million. More importantly, the company needs to signal a strong likelihood of exceeding the upper end of its recently raised full-year 2026 screening revenue guidance of $198 million, potentially indicating a new trajectory towards or above $200 million. | Achieving this threshold signals Guardant Health's Shield test is gaining market traction faster than anticipated, validating its commercial strategy and recent wins. This accelerates the screening business's path to profitability, enhancing competitive position and justifying a higher valuation multiple. | $53 million (253.3% y/y growth) | Partially | Q2 2026 Screening Revenue was $53 million, slightly below the ideal target of at least $55 million. However, the company raised its full-year 2026 screening revenue guidance to a range of $218 million to $230 million, which substantially exceeds the prior upper end of $198 million and indicates a new trajectory above $200 million. | |
Key QuestionsWill the expanded commercial coverage for Shield, driven by UnitedHealth Group and ACS guidelines, translate into sustained and accelerated volume growth in Q3
Will the expanded commercial coverage for Shield, driven by UnitedHealth Group and ACS guidelines, translate into sustained and accelerated volume growth in Q3 and Q4 2026, and how will the increasing mix of commercially insured patients impact Shield's average selling price (ASP) and overall gross margin trajectory given the new lower-COGS workflow?
- Question 2
Can Guardant Health secure MolDx reimbursement for Reveal in breast cancer surveillance and/or immuno-oncology monitoring by year-end 2026, and will the phased rollout of the FDA-approved Guardant360 Liquid CDx and the upcoming launch of Reveal Ultra further accelerate oncology volume growth and contribute to the anticipated Guardant360 ADLT ASP uplift in 2027?
- Question 3
Despite the increased full-year 2026 free cash flow burn guidance due to accelerated Shield investments, can Guardant Health demonstrate a clear path to reducing its overall cash burn in the second half of 2026, leveraging the new lower-COGS Shield workflow and the eventual Guardant360 ADLT ASP uplift, to remain on track for company-wide cash flow breakeven by the end of 2027?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Advancing the Smart Platform vision and achieving key regulatory milestones: Management highlighted the FDA approval for Guardant360 Liquid CDx and a higher-throughput, lower-COGS Shield workflow as landmark achievements. They also emphasized the inclusion of Shield in American Cancer Society's colorectal cancer screening guidelines and UnitedHealth Group's major coverage decision. 2. Driving broad-based growth across all business lines, especially Screening and Reveal: Management repeatedly mentioned strong and accelerating volume growth in Oncology (Guardant360 Liquid, Guardant360 Tissue, and Reveal), with Reveal being the fastest-growing product (over 100% Y/Y volume growth). They also highlighted the 'fantastic quarter for Shield' with significant revenue and volume growth, driven by commercial scale, DTC momentum, and the Quest collaboration. 3. Achieving profitability and improving cash flow while investing for future growth: Management reiterated their commitment to reaching company-wide cash flow breakeven by the end of 2027. They discussed operational efficiencies like the NovaSeq X transition for Guardant360 Liquid and the new Shield workflow to reduce costs, while also accelerating investments in lab capacity for Shield due to strong demand. | Call Takeaway & ToneGuardant Health delivered a strong second quarter in 2026, with significant year-over-year revenue growth across all segments, driven by accelerating oncology volumes (especially Reveal) and exceptional performance from the Shield screening business. Key regulatory and coverage milestones for Shield (ACS guidelines, UnitedHealth Group coverage, FDA approval of new workflow) are expected to further expand market access and improve cost efficiency. The company raised its full-year revenue guidance, demonstrating increased confidence in its commercial execution and product pipeline, while remaining committed to achieving company-wide cash flow breakeven by the end of 2027. The tone of the call was highly positive and confident. Management expressed excitement about the 'landmark quarter,' 'tremendous' growth, and 'fantastic' performance, underscoring the validation of their Smart Platform vision and commercial strategies. Analysts also offered congratulations on the 'great broad-based performance' and 'impressive growth.' | Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q1 2026): up 48% year-over-year. Oncology Revenue (Q1 2026): up 36% year-over-year. Biopharma & Data Revenue (Q1 2026): up 17% year-over-year. Screening Revenue (Q1 2026): up 600% year-over-year. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Impact of UnitedHealth Group (UHG) coverage and ACS guidelines on Shield's volume and ASP, and USPSTF timeline: Analysts questioned the near- and long-term impact on ASP and volume, and the implications for USPSTF. Management responded that UHG coverage and ACS guidelines open the market to approximately 70 million lives (60% of the market) and could be a 'tailwind for the volume,' helping build the commercial side. However, ASP impact will take time due to negotiation and collection history. They maintained their prior USPSTF expectation, noting that some payers are engaging even before USPSTF. 2. Drivers of continued strong Oncology volume growth, particularly Guardant360 and Reveal, and the Q3 outlook: Analysts asked about the puts and takes for the 50% Oncology volume guide and the per-patient testing cadence, especially given tough comps for Guardant360. Management attributed the strong growth to broad-based performance across Guardant360 Liquid (over 30% Y/Y volume growth), Guardant360 Tissue (accelerated growth), and Reveal (over 100% Y/Y volume growth). They expressed confidence in continuing this momentum to hit the 50% full-year volume growth target despite tough comps. 3. Guardant360 ADLT pricing, its impact on ASP and profitability, and the reinvestment strategy: Analysts inquired about the expected ADLT price of Guardant360, the potential ASP uplift, and how much of the incremental gross profit would drop to the bottom line versus being reinvested. Management confirmed an expected ADLT price of $8,455, an uplift from the current Medicare price of $5,000. They anticipate it will take 12-24 months for Medicare Advantage and commercial payers to align. They stated that some of the incremental gross profit would drop to the bottom line, potentially accelerating their path to breakeven (currently Q4 2027), while also being reinvested in innovation and commercial operations. | Revenue SegmentsTotal Revenue: $335 million, up 44% year-over-year. Oncology Revenue: $219 million, up 38% year-over-year. Biopharma & Data Revenue: $61 million, up 9% year-over-year. Screening Revenue: $53 million, up 253.3% year-over-year (from $15 million in Q2 2025). |
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Accelerating growth across the oncology portfolio, particularly Guardant360 and Reveal: Management highlighted Guardant360's 36% year-over-year revenue growth and 47% volume growth, driven by Smart platform innovation and InfinityAI. Reveal was the fastest-growing product with over 100% volume growth, reflecting strong adoption in MRD and therapy response monitoring. [cite: Helmy Eltoukhy] 2. Scaling the Shield screening business and expanding market reach: Management emphasized the "phenomenal start" for Shield with $42 million revenue and 44,000 tests, fueled by improved sales rep productivity, DTC and influencer campaigns (e.g., Patrick Dempsey), and the nationwide Quest collaboration. They also noted the launch of Shield Multi-Cancer Detection in Asia. [cite: AmirAli Talasaz] 3. Achieving key reimbursement and regulatory milestones to drive future growth and ASP upside: Management is focused on MolDx submissions for Reveal (breast cancer surveillance, immuno-oncology monitoring, chemotherapy monitoring) and FDA approval for Guardant360 Liquid, which is expected to be a significant volume catalyst and simplify ordering. [cite: Helmy Eltoukhy, Michael Bell] | Call Takeaway & ToneThe overall takeaway from the call is that Guardant Health delivered a "remarkable" Q1 2026, exceeding expectations with strong and broad-based revenue growth across all segments, particularly driven by the accelerating momentum in its oncology portfolio (Guardant360 and Reveal) and the rapidly scaling Shield screening business. Management raised its full-year 2026 revenue guidance, reflecting increased confidence in its commercial execution, strategic partnerships (Quest, Manulife), and product pipeline. The tone of the call was highly positive and confident, emphasizing the validation of their strategic vision, the "new level of velocity" in their commercial flywheel, and a clear path towards profitability for the core business and company-wide cash flow breakeven by the end of 2027. [cite: Helmy Eltoukhy, Michael Bell] | Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q4 2025): 39% year-over-year. [cite: Michael Bell, 10] Oncology Revenue (Q4 2025): 30% year-over-year. [cite: Michael Bell, 10] Biopharma & Data Revenue (Q4 2025): 9% year-over-year. [cite: Michael Bell, 10] Screening Revenue (Q4 2025): 756.1% year-over-year (from $4.1 million in Q4 2024 to $35.1 million in Q4 2025). [cite: Michael Bell, 10] | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. Shield's accelerated volume momentum and the impact of the Quest collaboration: Analysts questioned the sustainability of the accelerated momentum seen in March and the specific contribution of Quest. Management responded that the strong March momentum, driven by DTC campaigns, influencer campaigns, and Quest going live, gives them confidence in the new guidance. They are still capturing data on Quest's incremental help but are counting on some positive contribution in their thoughtful guidance. [cite: Mark Massaro, AmirAli Talasaz] 2. Drivers of Guardant360's continued strong growth (30% Y/Y volume) despite being on the market for a decade: Analysts asked for more color on what is driving this "outsized growth." Management attributed it to the fundamental step change in capabilities offered by the Smart liquid biopsy platform, allowing for phenotype insights and new applications. They noted broad-based growth, share gains, and expanding breadth and depth of physician adoption, emphasizing that they are still in the early innings of the platform's capabilities. [cite: Subhalaxmi Nambi, Helmy Eltoukhy] 3. Reveal's over 100% growth, key market drivers, and upcoming reimbursement catalysts from MolDx submissions: Analysts inquired about the factors behind Reveal's rapid growth and the timeline/catalyst set for MolDx coverage. Management explained that growth is strong across CRC, breast, and lung cancers in the surveillance setting, with therapy monitoring also being a significant addition. They stated that progress is being made with MolDx submissions for breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring, and favorable outcomes would provide "ASP upside" for the MRD business. [cite: Patrick Donnelly, Helmy Eltoukhy, Michael Bell] | Revenue SegmentsTotal Revenue: $302 million, up 48% year-over-year. [cite: Helmy Eltoukhy] Oncology Revenue: $205 million, up 36% year-over-year. [cite: Helmy Eltoukhy] Biopharma & Data Revenue: $53 million, up 17% year-over-year. [cite: Helmy Eltoukhy] Screening Revenue: $42 million, up 600% year-over-year (from $6 million in Q1 2025). [cite: AmirAli Talasaz] |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Driving adoption and expanding capabilities in oncology**: Management highlighted exceptional growth in their oncology business due to new capabilities and insights from Smart Platform applications, including Guardant360 Liquid, Guardant360 tissue upgrades, and Medicare coverage for Reveal in CRC surveillance. They are also excited about Reveal for therapy monitoring and its synergistic potential with Guardant360. [cite: Helmy Eltoukhy] 2. **Scaling the Shield screening business**: Management emphasized Shield's extraordinary growth since launch, driven by strong demand, the expansion of their commercial organization, and strategic partnerships with Quest Diagnostics and PathGroup. They also noted the securing of ADLT pricing. [cite: AmirAli Talasaz, Michael Bell] 3. **Strengthening path to profitability and improving cash flow**: Management reported improved non-GAAP gross margin and reduced free cash flow burn. They expect the core business (excluding screening) to be free cash flow positive for the full year 2026 and are committed to achieving company-wide cash flow breakeven by the end of 2027. [cite: Michael Bell] | Call Takeaway & ToneThe overall takeaway from the call is that Guardant Health delivered strong financial results in Q4 and full-year 2025, driven by robust performance in its oncology business and the rapid scaling of its Shield screening product. Management provided an optimistic outlook for 2026, projecting continued strong revenue growth and emphasizing strategic investments in key growth drivers, particularly in screening. They also highlighted a clear path to profitability for the core business and a commitment to company-wide cash flow breakeven by the end of 2027. The tone of the call was **positive and confident**, underscoring strong execution, successful product launches, and impactful strategic partnerships, while also acknowledging the necessary ongoing investments in the screening segment. | Prior Quarter'S Y/Y Growth By SegmentIn Q3 2025, total revenue increased 39% Y/Y. Oncology revenue grew 31% Y/Y. Biopharma and data revenue increased 18% Y/Y. Screening revenue grew 2310% Y/Y (from $1.0 million in Q3 2024 to $24.1 million in Q3 2025). | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Reveal therapeutic monitoring opportunity**: Analysts asked about the opportunity for Reveal therapeutic monitoring for both Reveal and Guardant360 volumes. Management responded that it's a significant opportunity to work synergistically with Guardant360, bridging to subsequent Guardant360 tests as patients progress, and that reimbursement wins for IO and chemo monitoring could be important growth drivers. [cite: Daniel Leonard, Helmy Eltoukhy] 2. **Shield specific burn and sales rep hiring pace**: Analysts inquired about the expected free cash flow burn for Shield and the pace of sales rep hiring. Management stated that Shield's burn for 2026 is expected to be similar to 2025 (around $220 million) due to continued heavy investments in commercial infrastructure. They plan to continue building out the commercial organization by reinvesting incremental gross profit into sales and marketing. [cite: Douglas Schenkel, Michael Bell, AmirAli Talasaz] 3. **Shield ASP decline and international contribution**: Analysts questioned the guided decline in Shield's average selling price (ASP) and the expected international contribution. Management explained that the ASP decline is primarily due to a mix impact from increasing demand from the under-65 population (non-Medicare), despite the ADLT rate being maintained for Medicare. They anticipate international contribution to Shield to be relatively small in 2026, with the majority of growth coming from the U.S. [cite: Tycho Peterson, Michael Bell] | Revenue SegmentsTotal revenue increased 39% year-over-year (Y/Y) to $281 million. Oncology revenue grew 30% Y/Y to $190 million. Biopharma and data revenue was up 9% Y/Y to $54.0 million. Screening revenue totaled $35.1 million from approximately 38,000 Shield tests; a specific Y/Y revenue growth percentage was not provided in the transcript, but it represents a significant increase compared to 6,400 tests in the prior year period. [cite: Michael Bell, 10] |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketGuardant Health's platform is enabling four of the largest opportunities in precision medicine: therapy selection, recurrence monitoring, cancer screening, and multi-disease screening, representing nearly $400 billion in potential markets. The company received FDA approval for Guardant360 Liquid CDx, which is the only FDA-approved liquid biopsy test integrating both genomic and epigenomic content, and will help simplify the therapy selection portfolio. Guardant360 Liquid CDx is on track to obtain ADLT designation in the first half of 2027. Shield was included in the American Cancer Society's colorectal cancer screening guidelines and received a major coverage decision from UnitedHealth Group, the largest commercial insurer in the United States, effective August 1 for adults 45 and older. These guideline inclusions and coverage decisions mean approximately 70 million lives, or roughly 60% of the U.S. addressable screening market, are now covered for Shield blood tests. Reveal continues to be the fastest-growing product with volume growth accelerating to more than 100% year-over-year, driven by MRD and therapy monitoring use cases, representing a multi-million test annual opportunity. The company has 28 companion diagnostic (CDx) approvals, with four added in the first half of 2026, including for Boehringer Ingelheim's HERNEXEOS and Arvinas and Pfizer's VEPPANU. Guardant is also collaborating with Nuvalent to develop companion diagnostics. Shield offers a multi-cancer detection results report covering nine additional cancer types, with the majority of ordering physicians opting in to receive these reports. MolDX submissions for Reveal coverage for breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring are progressing. Reveal Ultra, expected to be the most sensitive tumor-informed MRD test, is on track to launch later this year. Guardant360 Tissue volume growth also accelerated in the quarter. | About CompetitionGuardant360 Liquid CDx reinforces Guardant's leadership in the field of liquid CGP testing, being the only FDA-approved liquid biopsy test integrating both genomic and epigenomic content. Reveal remains the most validated and highest performing tissue-free MRD solution with a 5-day turnaround time. The upcoming Reveal Ultra is expected to be the most sensitive tumor-informed MRD test. The market for Reveal Ultra is described as 'highly competitive'. | About The Broader IndustryThe platform Guardant has built is enabling four of the largest opportunities in precision medicine: therapy selection, recurrence monitoring, cancer screening, and multi-disease screening. The company believes the future of oncology involves moving from biopsies and scans to using blood quantitatively to both treat and monitor patient response to therapy. In the payer landscape, there's a dynamic where 'nobody want to be first, nobody want to be last'. The broader industry is experiencing a paradigm shift in oncology, with the belief that 'the future of oncology and the future of therapy switching will involve ctDNA'. | Where Things Are HeadedGuardant Health is raising its full year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, representing 36% to 38% year-over-year growth. Oncology revenue growth is now expected to be approximately 30%, with volume growth of approximately 50%. Biopharma & Data outlook remains unchanged at low double-digit growth. Screening revenue guidance is raised to a range of $218 million to $230 million, with 270,000 to 285,000 Shield tests expected. The full year non-GAAP gross margin outlook remains 64% to 65%. Non-GAAP operating expenses are now expected to be $1.08 billion to $1.1 billion, representing 20% to 22% growth compared with 2025. The company expects full year free cash flow burn of $195 million to $205 million, an improvement compared with 2025. Guardant remains committed to achieving company-wide cash flow breakeven by the end of 2027. The higher-throughput, lower-COGS Shield workflow will be live in production in August for all new incoming samples, and is expected to reduce Shield cost per test by roughly 15% from the current level of approximately $410 by the end of 2026, targeting $200 per test in 2028. Guardant360 Liquid CDx is on track to obtain ADLT designation in the first half of 2027. The company expects a Guardant360 ADLT price of $8,455, which could lead to a long-term ASP of around $5,000. The ESR1 monitoring launch remains contingent on FDA approval of camizestrant. USPSTF inclusion for Shield is still anticipated in a late 2027 or early 2028 timeframe. | Updates On ThemeDiagnostics | Bullish-Leaning Quotes (Short)Q2 was a landmark quarter in advancing that vision. We delivered $335 million of revenue in the second quarter, representing 44% year-over-year growth. Reveal continues to be our fastest-growing product with volume growth accelerating again to more than 100% year-over-year. The FDA approval in the second quarter represents one of the most significant regulatory milestones in our company's history. UnitedHealth Group, the largest commercial insurer in the United States, announced it will begin covering Shield for colorectal cancer screening in adults 45 and older. We received FDA approval for a higher-throughput, lower-COGS Shield workflow. We are raising full year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, representing growth of 36% to 38%. We remain committed to achieving company-wide cash flow breakeven by the end of 2027. | Bearish-Leaning Quotes (Short)These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. ASP is going to take some time, though, like ASP in order to see the impact, we need to obviously go through some kind of conversations with them, but also show the history of collection from them in order to be able to accrue some of the upside upfront. Still, we don't expect any major wins in short term by any other major payers. We don't want to get ahead of our skis with the fantastic Q2 results that we have for rest of the year and be very thoughtful. We don't expect any major wins for the rest of the year. We haven't included anything in our guide in terms of additional wins. ESR1 monitoring launch remains contingent on FDA approval of camizestrant. Obviously, it's taking a little bit longer than we would have liked [for MolDX submissions]. | HiringThe field organization now stands at over 400 professionals nationwide. Sales and marketing expense increased to $172 million from $108 million a year ago as the company continues to expand the Screening sales infrastructure, advance Shield HCP and DTC programs, and support Oncology growth. Guardant is accelerating investments to continue to build lab capacity ahead of rapidly increasing volume. The company intends to continue to reinvest incremental Screening gross profit to support commercial expansion. CapEx investment in screening lab automation and broader infrastructure is increasing to support higher test volumes, greater processing efficiency, and improved turnaround times. The company also plans to continue investing in commercial operations on the Oncology side of the business. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketGuardant Health's Guardant360 Liquid, upon FDA approval, is set to become the most comprehensive FDA-approved liquid biopsy for therapy selection on the market. The company also announced a second major platform upgrade for Guardant360 Tissue, expanding RNA testing to whole transcriptome, which is expected to be a meaningful volume catalyst by converting current nonusers. Reveal is seeing strong adoption in MRD across indications and enthusiasm for its new therapy response monitoring use case. Data packages have been submitted to MolDx to support coverage for Reveal in breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring, with ongoing studies across more than 5 additional tumor types. The CDx franchise now spans 26 approvals across the U.S., Japan, and Europe, including recent FDA approvals for Guardant360 CDx with Pfizer's Braftovi and Arvinas and Pfizer's VEPPANU. Real-world evidence from InfinityAI contributed to the first tumor-agnostic approval of Daiichi Sankyo's ENHERTU in Japan. Strategic partnerships include a multiyear agreement with Merck and a collaboration with Nuvalent to develop companion diagnostics. The Shield Multi-Cancer Detection report, covering 9 additional cancer types, has launched in Asia through a partnership with Manulife in Hong Kong, the Philippines, and Singapore. The nationwide Quest collaboration is opening doors in health systems and physician practices where Guardant Health previously lacked a strong direct presence, and EMR connectivity has expanded to more than 650,000 HCPs. Additionally, the FDA approved reducing the Shield blood collection to 2 tubes from the original 4-tube kit to enhance patient experience. | About CompetitionGuardant Health believes it has been "leading the pack, frankly, in terms of real AI that has that actionable insight." The company noted that when launching new products, they tend to see "out-sized traction maybe versus, let's say, a new competitor in the market." In response to a question about consolidation and competitors like Roche with Saga and Abbott with Exact, management stated that "the bar is very high in terms of what we built organically inside the company, the growth rates, the quality of our products and so on." The company also highlighted that it is "the far and away leader in tissue-free MRD." The sales field is acknowledged as "becoming competitive." | About The Broader IndustryThe broader industry is experiencing a paradigm shift in oncology, with the belief that "the future of oncology and the future of therapy switching will involve ctDNA." It was noted that "it's always hard for the first paradigm shift" and that a "mountain of evidence" is required when moving from one modality to another, but once the dam is broken, it's hard to go back. The market for MRD is described as having "2 parts to it. The consumer-informed sort of MRD subset and then certainly market as well that is very, very sizable." | Where Things Are HeadedGuardant Health is raising its full year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, representing 32% to 34% growth. Oncology revenue is expected to grow 28% to 29% with volume growth greater than 35%, with Reveal remaining the fastest-growing oncology product. Biopharma & Data revenue is projected for low double-digit growth. Screening revenue is now expected to be $186 million to $198 million, driven by 230,000 to 245,000 Shield tests. The company anticipates a full year non-GAAP gross margin of 64% to 65% and non-GAAP operating expenses in the range of $1.05 billion to $1.07 billion. Free cash flow burn for 2026 is expected to improve to $185 million to $195 million, and the company remains committed to achieving company-wide cash flow breakeven by the end of 2027. Key upcoming initiatives include completing the Guardant360 Liquid NovaSeq X transition in May 2026, launching Reveal Ultra and FDA-approved Guardant360 Liquid, and continued expansion of the Smart platform. ACS guideline inclusion for Shield is expected in the near term. Shield's cost per test is expected to decline to approximately $200 at scale, driven by further volume growth and workflow efficiencies and automation anticipated in 2027. | Updates On ThemeData | Bullish-Leaning Quotes (Short)Our commercial flywheel has achieved a new level of velocity, delivering our fastest year-over-year percentage revenue growth in the last 5 years and surpassing the $1 billion trailing 12-month revenue milestone. We had a phenomenal start to 2026, delivering $302 million of revenue in Q1, representing 48% year-over-year growth. Reveal remained our fastest-growing product with volumes up over 100% year-over-year. Guardant360 Liquid will become the most comprehensive FDA-approved liquid biopsy for therapy selection on the market. Q1 was another strong quarter for Shield. We delivered $42 million of Shield testing revenue driven by approximately 44,000 tests compared to $6 million revenue and approximately 9,000 tests in Q1 of 2025. We are raising our full year 2026 revenue guidance to a range of $1.30 billion to $1.32 billion, representing growth of 32% to 34%. We remain committed to achieving company-wide cash flow breakeven by the end of 2027. I feel like we've been leading the pack, frankly, in terms of real AI that has that actionable insight. | Bearish-Leaning Quotes (Short)These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Our oncology guidance does not include potential upside from FDA approval of Guardant360 Liquid or the launch of Reveal Ultra. Our revenue guidance does not reflect any impact from the potential approval of camizestrant. Oncologic Drugs Advisory Committee voted [6 to 3] against the claim that camizestrant demonstrated clinically meaningful benefit. Our screening guidance does not include upside from ACS guideline inclusion. We typically don't want to get too excited and get ahead of our skis just based on 1 quarter performance. The field is becoming competitive. | HiringGuardant Health plans to continue hiring sales representatives, noting that the quality of reps being hired continues to improve. On the oncology side, the company may split territories and add additional reps and support staff where there is no saturation and positive ROI. Incremental screening gross profit will be reinvested to support commercial expansion, including building out the sales and marketing function. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketGuardant Health introduced groundbreaking applications for Guardant360 Liquid, upgraded Guardant360 tissue onto their smart platform, and expanded Reveal to support therapy monitoring. The company applied Infinity AI to develop 15 smart applications on Guardant360 liquid, which are believed to meaningfully expand its clinical utility and leadership in the liquid CGP market. Global access was expanded in Q4 with the launch of Guardant360 CDx technology in Rome, Italy. Reveal received Medicare coverage for CRC surveillance in early 2025 and is generating clinical data for additional reimbursement coverage this year, with early uptake for late-stage therapy response monitoring broadening its clinical use. Data packages have been submitted to support coverage in breast cancer surveillance, immuno-oncology monitoring, and chemo monitoring, with ongoing studies across more than 5 additional tumor types. Shield expanded to include a multi-cancer detection results report and received TRICARE coverage for eligible average-risk individuals aged 45 and older. The company successfully deployed its first enterprise-scale integrations with large health systems in West Virginia and Georgia and announced collaborations with Quest Diagnostics and PathGroup to broaden national reach in 2026. There are also plans for expansion of self-pay Shield into select markets outside the U.S. In biopharma, Guardant Health is a leader in companion diagnostics with 25 approvals and a robust pipeline, including 5 new CDx approvals for Guardant360 in the last 6 months, and a multiyear agreement with Merck. | About CompetitionGuardant Health believes it is building a meaningful competitive moat in its oncology business through the combined strength of Guardant360 and Reveal, being uniquely positioned with scaled offerings spanning both treatment selection and monitoring. Shield's 93% adherence rate represents a meaningful improvement compared to other screening modalities, which typically range from 25% to 71%. The upcoming Reveal Ultra is expected to redefine sensitivity in the tumor-informed space. The company noted that a competitor's large multi-cancer early detection (MCED) trial did not meet its primary endpoint in terms of looking for stage shift. | About The Broader IndustryThere is a growing role for blood-based monitoring in cancer care. Legislation establishing a Medicare coverage pathway for multi-cancer detection tests has recently passed. The broader industry is experiencing a shift towards personalized medicine and early cancer detection, driving increased demand for advanced diagnostic solutions. CMS premium pricing (ADLT) and broad Medicare coverage for blood-based CRC and follow-on Cologuard 2, along with the Trump-era rollback of LDT rules, are accelerating payer uptake of ctDNA/MCED and AI-enabled pathology. | Where Things Are HeadedFor full year 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing 27% to 30% growth, positioning them to achieve their 2028 long-range revenue target of $2.2 billion. Oncology revenue growth is projected at 25% to 27% in 2026, with volume growth of approximately 30%, and Reveal is expected to remain the fastest-growing oncology product. Biopharma and data revenue is forecasted for low double-digit growth in 2026. Screening revenue is expected to be in the range of $162 million to $174 million from 210,000 to 225,000 tests in 2026. The core business (excluding screening) is expected to be free cash flow positive for the full year 2026, with the company committed to achieving company-wide cash flow breakeven by the end of 2027. Free cash flow burn for 2026 is anticipated to improve to $185 million to $195 million. Upcoming oncology product launches include Guardant360 Liquid CDx, an ESR1 monitoring test, and Reveal Ultra. In screening, the company anticipates inclusion in ACS guidelines, commercial expansion with Quest, and international self-pay Shield expansion. The transition of Guardant360 liquid tests to NovaSeq X is expected to be fully implemented around the middle of 2026. | Updates On Theme**HC | Bullish-Leaning Quotes (Short)2025 was a breakout year for Guardant, where years of investment continues to fuel breakthrough innovation and best-in-class execution across our portfolio. This exceptional performance reflects continued broad-based growth across our oncology screening and biopharma and data businesses. Shield is the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver for Guardant. We expect the core business to be free cash flow positive for the full year 2026 and remain committed to achieving company-wide cash flow breakeven by the end of 2027. We're feeling really good about how we're sort of managing the burn. | Bearish-Leaning Quotes (Short)These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This is just the second year of launch, and we want to be thoughtful with our guidance. We typically don't want to get too excited and get ahead of our skis just based on 1 quarter performance. Q1 seasonality in PCP offices is kind of normal. Our screening guidance does not include potential upside from Quest co-promotion activities as well as ACS guideline inclusion. | HiringGuardant Health significantly expanded its commercial team and established strategic partnerships to meet growing demand for blood-based screening. The commercial organization for Shield scaled throughout 2025, exiting the year with approximately 300 sales reps, and will continue to build out in 2026, with incremental gross profit invested in sales and marketing, primarily for building the sales force and hiring more people. The acquisition of MetaSight Diagnostics also brought on an impressive team, strengthening the world-class R&D organization. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-19 | Guardant Health reported strong Q4/FY25 revenue and volume growth, with Shield exceeding expectations and the core business achieving positive free cash flow. The company issued bullish 2026 guidance, projecting continued expansion and a path to profitability. However, the stock significantly underperformed the market post-earnings, suggesting investor skepticism regarding the pace of profitability or the aggressive investment in screening despite positive operational updates. | Other | Neutral | -3.08% (vs SPY: -2.77%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| GH_707b8be0 | later this year | 2026-10-01 | 2026-12-31 | Guardant Health plans to launch Reveal Ultra, which is anticipated to be the most sensitive tumor-informed MRD test. | This new product launch is expected to redefine sensitivity in the tumor-informed MRD space, enhancing Guardant Health's competitive position and driving further volume growth in the MRD market. | Ticker | 2026-07-30 | earnings_transcript |
| GH_8850e4c8 | following ADLT designation | 2027-01-01 | 2027-06-30 | Guardant Health plans to offer widespread availability of Guardant360 Liquid CDx to U.S. customers. | This commercial rollout, following ADLT designation, will drive greater adoption of the test, simplify the therapy selection portfolio, and contribute to oncology volume growth. | Ticker | 2026-07-30 | earnings_transcript |
| GH_4fe268e1 | first half of 2027 | 2027-01-01 | 2027-06-30 | Guardant Health remains on track to obtain ADLT designation for Guardant360 Liquid CDx. | This designation is expected to lead to an immediate increase in the average selling price (ASP) for Guardant360, improving gross margins and potentially accelerating the company's timeline to cash flow breakeven. | Ticker | 2026-07-30 | earnings_transcript |
| GH_4e822abd | 2026–2027 timeframe | 2026-07-01 | 2027-12-31 | AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive. | Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative. | Ticker | 2026-02-19 | earnings_transcript |
| GH_a329742a | pending FDA approval; timing to be determined (2026 or later) | 2026-01-01 | 2027-12-31 | Guardant360 Liquid CDx launch following FDA approval. | Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk. | Ticker | 2026-02-19 | earnings_transcript |
| GH_551c816d | in 2026 | 2026-01-01 | 2026-12-31 | Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | 2026-02-19 | earnings_transcript |
| GH_17aaaacc | near term (2026) | 2026-01-01 | 2026-12-31 | ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption. | Could drive Shield volumes and broaden market access, supporting volume growth. | Ticker | 2026-02-19 | earnings_transcript |